|
gptkbp:instanceOf
|
gptkb:antibiotic
cyclic polypeptide
|
|
gptkbp:administeredBy
|
animals
humans
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
D06AX09
|
|
gptkbp:CASNumber
|
1405-87-4
|
|
gptkbp:chemicalClass
|
polypeptide antibiotic
|
|
gptkbp:compatibleWith
|
oral administration
|
|
gptkbp:contraindication
|
hypersensitivity to bacitracin
|
|
gptkbp:discoveredBy
|
gptkb:Balbina_Johnson
|
|
gptkbp:discoveredIn
|
1945
|
|
gptkbp:eliminationHalfLife
|
6 hours (IM)
|
|
gptkbp:firstIsolatedFrom
|
wound of a compound fracture
|
|
gptkbp:foundIn
|
Neosporin (in some countries)
|
|
gptkbp:hasMolecularFormula
|
C66H103N17O16S
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
bacitracin
|
|
gptkbp:includedIn
|
triple antibiotic ointment
|
|
gptkbp:KEGGID
|
D00132
|
|
gptkbp:legalStatus
|
Rx-only (injection)
OTC (topical)
|
|
gptkbp:mechanismOfAction
|
inhibits cell wall synthesis
|
|
gptkbp:MeSH_ID
|
D001353
|
|
gptkbp:nameOrigin
|
Bacillus + Tracy (name of patient)
|
|
gptkbp:notEffectiveAgainst
|
fungi
viruses
Gram-negative bacteria
|
|
gptkbp:notRecommendedFor
|
systemic use
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:producedBy
|
gptkb:Bacillus_licheniformis
gptkb:Bacillus_subtilis
|
|
gptkbp:PubChem_CID
|
CHEMBL1201207
5280960
DB00621
|
|
gptkbp:riskFactor
|
nephrotoxicity (systemic use)
|
|
gptkbp:routeOfAdministration
|
topical
intramuscular
|
|
gptkbp:sideEffect
|
gptkb:contact_dermatitis
allergic reaction
nephrotoxicity (when systemic)
|
|
gptkbp:solubility
|
water-soluble
|
|
gptkbp:spectrumOfActivity
|
Gram-positive bacteria
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:UNII
|
I7G10O7R7N
|
|
gptkbp:usedFor
|
treatment of bacterial infections
|
|
gptkbp:usedIn
|
gptkb:veterinary_medicine
dermatological preparations
ophthalmic preparations
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Bacillus_subtilis
|
|
gptkbp:bfsLayer
|
6
|